Vision Loss Drug Vabysmo Secures English Funding; Oxlumo & Tavneos Deemed Too Pricey

Roche’s Vabysmo is likely to be cost saving, according to NICE, which has also issued recommendations on the use of the drugs Oxlumo, Tavneos, Libtayo, Tepmetko and Ryeqo.

 Share   close up view of human eye with data illustration, robotic concept
Vabysmo is approved for treating the eye diseases wet AMD and DME • Source: Alamy

Health technology assessment institute NICE has recommended that Roche’s Vabysmo (faricimab) be funded via the National Health Service in England, where thousands of people with wet age-related macular degeneration (AMD) or diabetic macular edema (DME) could be eligible to receive the VEGF therapy.

By contrast, it advised that Alnylam Pharmaceuticals’ Oxlumo (lumasiran), for primary hyperoxaluria type 1 (PH1), and Vifor Pharma’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe